Context: Pain is one of the most devastating symptoms for cancer patients. One third of patients who experience pain do not receive effective treatment. A key barrier to effective pain management is lack of routine measurement and monitoring of pain. Patient-reported outcome measures (PROMs) are recommended for measuring cancer pain. However, evidence to guide the selection of the most appropriate measure to identify and monitor cancer pain is limited. A systematic review of measurement properties of PROMs for pain in cancer patients is needed to identify the best validated measure for adoption to an electronic platform. Objectives: To systematically review measurement properties of PROMs used for adult cancer patients to measure pain and, as a secondary goal, to investigate the evidence of validated mobile health (mHealth) applications used to measure pain (registration number: CRD42017065575). Methods: Medline, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) were systematically searched in March 2018 for studies examining measurement properties for PROMs for pain in adult cancer patients. The methodological quality of the studies and their results were appraised using the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) checklist and specific measurement properties criteria, respectively. Results: Sixteen studies evaluating 8 instruments were included. No studies using a PROM in an mHealth application were identified. The methodological quality of the measurement properties ranged between poor and fair. No instrument showed strong positive evidence for all the evaluated measurement properties. Based on the available evidence, the Brief Pain Inventory-Short Form (BPI-SF) had the strongest evidence to support its selection for the measurement of cancer pain. Conclusion: The BPI-SF was the best performing measure across all properties evaluated through COSMIN. Better quality validation studies of PROMs for cancer pain are needed to explore the full range of measurement properties. Utilizing mHealth applications to measure pain in cancer patients is an innovative approach worthy of further investigation. &
INTRODUCTION
Pain is one of the most devastating symptoms for patients throughout the cancer trajectory. 1 The World Health Organization's (WHO's) analgesic 3-step ladder is the definitive clinical principle for cancer pain management. 2 It has been used since 1986, and involves a stepwise approach to analgesic prescriptions for cancer pain. 3, 4 Despite improvements in pain management with this strategy, 5, 6 some cancer patients still experience high levels of pain in situations where it is possible to reduce suffering. Around 25% to 33% of cancer patients receive insufficient pain management. 7, 8 Two systematic reviews
that assessed the quality of pain management in adult cancer patients revealed modest improvements in pain management between 2008 and 2014, but showed that one-third of patients who experience pain are undertreated. 9, 10 Inadequate pain assessment is considered a significant barrier to sufficient pain management. 11, 12 Therefore, pain management guidelines emphasize routine and systematic pain assessment, including documenting a detailed pain history and medication efficacy. 12, 13 Measuring and documenting pain every 4 hours for each patient for 5 weeks improved pain assessment (from 42% to 71%) and pain management (from 59% to 97%) for patients in intensive care units (ICUs), including oncologic surgery ICU. 14 Assessing and recording pain regularly may be appropriate given that a patient is more likely to forget such details about pain after receiving care. In particular, retrospective scores of pain are known to be significantly higher than contemporaneous diary report of pain. 15 Patient-reported outcome measures (PROMs) are recommended for measuring cancer pain. 16 PROMs are frequently presented as questionnaires that are completed by patients to measure health-related constructs. 17 Various PROMs are used for assessing pain in patients with cancer, including the Brief Pain Inventory (BPI), [18] [19] [20] [21] McGill Pain Questionnaire (MPQ), [22] [23] [24] numeric rating scale (NRS), 1, [25] [26] [27] and visual analog scale (VAS). [26] [27] [28] With the number of these instruments increasing, it is more challenging to identify which is the most appropriate one for use in a clinical or research setting. Systematic reviews of measurement properties are useful for critically appraising and comparing the content and measurement properties of all available tools measuring a specific construct to understand their strengths and limitations and make an informed choice.
29,30
The Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) group is a committee that aims to improve the selection of health-related measurement instruments by forming tools and guidelines, based on international experts' consensus, for conducting or assessing a systematic review of measurement properties. [29] [30] [31] The need for such standards was identified in 2009 through reviewing systematic review studies of health status measurement instruments. The methods used to assess the quality of the studies and the quality of the results differed widely, and the methodological quality of such reviews should be improved. 30 The COSMIN tools include a protocol for systematic reviews of measurement instruments, a checklist to assess the methodological quality of studies, and quality criteria for measurement properties. [31] [32] [33] [34] [35] Indeed, the quality of both validation studies and their results (measurement properties) is important to appraise instruments for a health construct. If the methodological quality of a study is inappropriate, the results cannot be trusted and the quality of the instrument remains unclear. 32, 36 Since measurement properties are essential for evaluating an instrument, 30 ,37 and they are not clearly defined in the literature, the COSMIN group provides international definitions. 31, 38 A systematic review of the measurement properties of the established tools for measuring pain in cancer patients is crucial to compare them and identify the best validated pain measure for this population. Very few reviews of this type have been conducted previously. Jensen (in 2003) conducted a review of the validity and reliability of pain measures for adult cancer patients, but it has several limitations. 39 The review was not systematic and is now outdated. Publications were from a 3-year period only, and their methodological quality was not clearly considered. There are systematic reviews of instruments related to the holistic symptoms of cancer 40 and quality of life (QoL). 41 For both types of study there has been no rigorous assessment or any consideration of the quality of the studies and their results. These instruments are not specific for pain in cancer patients. Indeed, QoL instruments usually measure multiple constructs and general health perceptions, and are not designed to be a specific pain measurement instrument, although they do contain symptom items. 30, 40 In addition, the WHO analgesic ladder is designed specifically for cancer patients. 3, 4 This implies that treatment of cancer pain requires an approach specific to cancer patients and that cancer patients are distinct from noncancer patients in the type of pain they experience. This relates largely to the meaning of the pain; cancer pain is often interpreted as an indicator of disease progression, and the association of pain with life-threatening disease is likely to account for why pain interference is ranked higher in cancer patients compared to noncancer patients, even when pain intensity is the same. 42 As a consequence, it is logical to have a specific pain tool for cancer patients.
Mobile health (mHealth) is an innovative and timely method for health monitoring and intervention in the home setting, which can be utilized in measuring pain, compared to existing approaches. This is because of the increasing use of mobile and smart device applications (apps) and social media. 43 ,44 mHealth has been described as the use of "mobile computing, medical sensor, and communications technologies for health care." 45 The rapid increase in mobile device use has been associated with similar expansion in the field of mHealth. For example, mHealth interventions including smartphone apps have been utilized in supporting selfmanagement and medication adherence for asthma, 46 Parkinson's disease, 47 lower back pain, 48 and chronic conditions. 49 For pain assessment and management in cancer patients, only a few mHealth interventions have been attempted. 1, [50] [51] [52] The aim of the current study was to systematically review the measurement properties of PROMs for pain used in adult cancer patients following the COSMIN framework and recommendations. A secondary goal is to investigate the evidence of validated mHealth apps or mobile electronic tools used to measure pain in adult cancer patients.
METHODS
The systematic review (registration number CRD42017065575 on PROSPERO, an international database of prospectively registered systematic reviews in health and other fields produced by Centre of Reviews and Dissemination at the University of York, U.K.) was conducted according to the guidelines from the Cochrane Handbook for Systematic Reviews, 36 in combination with the protocol for systematic reviews of measurement properties recommended by the COS-MIN panel.
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Search Strategy
In accordance with the Cochrane guidelines, the population, intervention, comparison, and outcome (PICO) concepts were applied to the research question. Adult (≥ 18 years of age) cancer patients were considered as the population (P); the intervention (I) was PROMs used to measure pain; the comparison (C) concept was not applicable to the research question since this would require an unmeasured arm; while the measurement properties defined by COSMIN were considered the outcomes (O) for this systematic review. There are 9 measurement properties grouped within 3 domains: reliability (internal consistency, reliability, and measurement error), validity (content validity, construct validity [or hypotheses testing], structural validity, cross-cultural validity, and criterion validity), and responsiveness 38 (see Appendix 1 for definitions of properties). The criterion validity was excluded for this review since no gold standards exist either for PROM instruments 54 or for measurements of pain. 55, 56 Medline (Ovid from 1996), Embase (Ovid from 1996), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCO from 1981) electronic databases were searched in March 2018. A search strategy was designed and performed using search terms that had been carefully specified after several consultations with a librarian and an information specialist. In accordance with the Cochrane review guidelines, a combination of index terms, such as MeSH in Medline, and free-text terms for each identified PICO concept was searched combined by the conjunction "OR." Then, the search results for all the concepts were combined by the conjunction "AND." To focus the search to retrieve PROM tools, the Oxford filter for PROMs developed by the PROMs Group 29,57 was used. The search was restricted to English language publications, with no time limitation. An example of the detailed search strategy applied on Medline is illustrated in Appendix 2. Additional papers were identified by manually searching the reference lists of the included primary studies and key review studies, as well as searching forward referencing of these studies using the Web of Science database.
Eligibility Criteria and Selection of Articles
Studies were selected based on the following criteria: a published primary validation study for a PROM used to specifically measure pain that reported 1 or more of its measurement properties, the instrument for which was administered on adult (≥ 18 years of age) patients with a definite cancer of any type. Studies that included patients with diseases other than cancer were excluded unless the results for the cancer patients were presented separately. PROMs that were specific to certain cancer types were excluded as the review aimed to select the best pain measurement tool for the wider cancer population. PROMs that were general (ie, measured pain within other constructs) or were indirectly related to pain (such as QoL, disease symptoms, and treatment satisfaction instruments) were excluded. Furthermore, the review excluded studies that validated measures based on measures of our interest, randomized controlled trials (RCTs), or other longitudinal studies, as recommended by the COSMIN protocol. Such studies usually provide indirect evidence, and it is difficult to assess validity or responsiveness. No hypotheses regarding the validity or responsiveness of the instrument of interest are formulated and verified in these studies. 31, 53 The results from the searched databases were accumulated in reference manager software (EndNote X7), where any duplicate articles were removed. The studies' titles and abstracts were scanned against the specified inclusion and exclusion criteria before the articles were read as full texts and re-examined for eligibility. The selection of studies was conducted independently through the 2 stages by 2 reviewers (A.A.A. and L.E.Z.), and any disagreements between them were resolved through discussion.
Quality Assessment of the Studies
The methodological quality of the included studies was evaluated and rated using the COSMIN checklist, which has a 4-point rating scale. 32, 33 The studies were rated by A.A.A. and L.E.Z. The checklist consists of 9 boxes representing the 9 measurement properties defined by the COSMIN panel. Each box has 5 to 18 items describing whether a study on a measurement property meets the standard for appropriate methodological quality. A score (poor, fair, good, excellent) was given to each item based on the level of adherence to a specific standard. The overall score for each measurement property was specified by considering the lowest score awarded to any item in the checklist box associated with the property. For example, if one item in the internal consistency box was graded as poor for a study, the overall methodological quality of this property was rated as poor. Each measurement property was rated separately.
Quality Assessment of the Instruments
The quality of the measurement properties of the instrument was assessed using the modified version of the quality criteria for good measurement properties published by the COSMIN panel.
29, 34 The possible ratings specified by these criteria for a measurement property are "positive," "indeterminate," or "negative" (Appendix 3). The measurement properties were assessed by A.A.A. and L.E.Z.
Best Evidence Synthesis
The strength of the evidence for the measurement properties for each tool was determined by considering the following: the number of studies, their methodological quality, and the consistency and quality of the results. 31, 53 The evidence of a measurement property was considered strong (positive or negative) when consistent findings were derived from multiple studies (at least 2) of good methodological quality, or by 1 study of excellent methodological quality; moderate (positive or negative) when consistent findings were derived from multiple studies of fair methodological quality, or from 1 study of good methodological quality; limited (positive or negative) when findings were derived from 1 study of fair methodological quality; conflicting when conflicting results were found in 2 or more studies; and unknown when findings were derived only from studies of poor methodological quality. A.A.A and L.E.Z. attributed the level of evidence for the tools.
Data Extraction
Two groups of data were extracted from each study and are reported in the tables. The first group, study characteristics, encompasses general information about the study and the evaluated instrument. This includes the authors (by reference number), year of publication, characteristics of the population among which the instrument was evaluated (disease, gender, mean age, settings, country, and language), and general features of the instrument as described by the study (name, construct, number of items, and version). The second data group, instruments' measurement properties, represents the results of the measurement properties of the tool reported by the study. All the necessary data were extracted by A.A.A. and L.E.Z.
RESULTS

Study Selection
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram 58 in Figure 1 shows the results from the literature search and the selection process. Sixteen validation studies of pain measurement instruments met the eligibility criteria. The review did not identify any studies that used a pain measurement instrument in a smartphone or tablet app oriented to adult cancer patients.
Study Characteristics
Eight pain measurement instruments were evaluated by the included studies. The characteristics of the studies and instruments are illustrated in Table 1 . Table 2 shows the results for measurement properties as reported by the studies.
Study Methodological Quality and Result Quality
The ratings of the methodological quality of the studies and the quality of the results per measurement property and instrument are reported in Table 3 . The strength of the evidence for each property per instrument is shown in Table 4 . Summaries are provided in the ensuing subsections.
Brief Pain Inventory. The BPI has 15 items and was evaluated in different languages in 8 studies, [59] [60] [61] [62] [63] [64] [65] [66] making it the most evaluated of all the instruments included in this review. The BPI was designed to measure the severity of pain and its impact on functioning of patients using an 11-point NRS. It also uses a drawing where patients mark the location of their pain, and asks about pain treatment and relief. 60 The majority of the studies identified 2 factors (severity and interference) for the BPI, using confirmatory factor analysis (CFA) to support structural validity. The quality of this result was rated negative because the ratio of the variance explained by the first to the second factors was < 4. This was consistent in multiple fair methodological studies, [61] [62] [63] leading to moderate negative evidence for structural validity. Indeed, the BPI structure validity was reported by an excellent methodological study, 59 but the findings were rated as indeterminate, as the percentage of variance explained by each factor was not provided. Therefore, this result was ignored for evidence synthesis. The evidence for construct validity Records after duplicates removed (n = 3398)
Records screened based on title and abstract (n = 3398)
Full-text articles assessed for eligibility (n = 25)
Full-text articles excluded, with reasons (n = 9) -Two are specific to particular types of cancer -Two have sample less than 18 years -Two are longitudinal studies -One is based on data derived from RCT study -One is a PhD thesis and no publications were found related to it -One is not a validation study
Studies included in the review (n = 16 evaluated 8 instruments)
Studies of mHealth interventions for adult cancer pain measurement (n = 0) Figure 1 . Preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram. 59 reported test-retest reliability. This means there is unknown evidence for the BPI's reliability property. On the other hand, internal consistency was addressed in all 8 studies and showed strong positive evidence.
BPI-Short Form (BPI-SF).
The BPI-SF has 11 items and was assessed in 3 studies. 23, 67, 68 It has the same 2 subscales as the BPI. This was confirmed by moderate positive evidence for structural validity. The latter was rated as positive (unlike the full version) because the first factor accounted for more than 20% of the variability, and the ratio of the variance explained by the 2 factors was > 4. Evidence for cross-cultural validity was unknown, as was the case with the original version. Assessment of construct validity and internal consistency properties showed moderate positive evidence.
McGill Pain Questionnaire. One study 69 assessed the MPQ and met the eligibility criteria of the review. The MPQ as described in the study has 4 subscales (sensory, affective, evaluative, and miscellaneous) with 24 items. The methodological quality for almost all the evaluated measurement properties was rated poor mainly because the sample size (N = 114) was inadequate (ie, not > 7 times the number of items). This gave unknown evidence for these properties (see Table 4 ).
MPQ-Short Form (MPQ-SF).
The MPQ-SF was validated in 1 study and has 2 subscales (sensory and affective) derived from the original MPQ, with 15 items. 23 It was unclear how missing items were handled through the analyses of this study, so the methodological quality for the evaluated measurement properties were rated as fair. There was limited positive evidence for internal consistency and structural validity and limited negative evidence for construct validity.
MPQ-SF-2. The MPQ-SF-2 is an update of the original version (MPQ-SF) that includes neuropathic qualities in addition to the sensory and affective qualities. 22 It has 4 subscales (continuous, intermittent, neuropathic, and Systematic Review of Measurement Properties 105 Table 2 . affective) with 24 items. It was assessed in 1 study, which showed excellent methodological quality for both internal consistency and structural validity. The findings for the latter were rated as negative, as a number of positive rating criteria were not met, including the Tucker-Lewis index, which was < 0.95. The methodological quality of the construct validity was rated as fair in this study because no hypotheses were formulated before testing, but it is possible to deduce what was expected. The evidence synthesis of the MPQ-SF-2 resulted in strong positive evidence for internal consistency, strong negative evidence for structural validity, and limited positive evidence for construct validity.
Location-Based Assessment of Sensory Symptoms in Cancer (L-BASIC).
The L-BASIC includes 4 items and was evaluated in 1 study. 70 The study tested 3 measurement properties, with fair methodological quality for internal consistency and reliability and poor methodological quality for construct validity. It was not clear how missing data were handled, and no information was given about the measurement properties of the comparator instruments. The evidence synthesis for the L-BASIC resulted in limited positive evidence for internal consistency and reliability, and unknown evidence for construct validity.
Cancer Pain Inventory (CPI). The CPI comprises 5 subscales (catastrophizing, interference, stoicism, social aspects, and pain medication) with 19 items. Three measurement properties for the instrument were tested in only 1 study, which was rated with fair methodological quality. No explanation was given of how missing data were handled. 71 The synthesis of evidence showed limited positive evidence for both internal consistency and construct validity and limited negative evidence for structural validity, as the ratio of the variance explained by the first to the second factor was < 4.
Brief 4-Week Pain Diary. The brief 4-week pain diary has 7 items in 2 subscales (pain and pain impact on QoL). It was evaluated in 1 study, 72 which tested internal consistency with poor methodological quality and tested construct validity with fair methodological quality. The study was rated thus because no factor analysis was performed, and there was no explanation of how missing items were handled. The synthesis of evidence resulted in unknown evidence for internal consistency and limited positive evidence for construct validity.
DISCUSSION
PROMs play an increasingly significant role in monitoring symptoms in cancer patients and can facilitate improvements in QoL through timely identification and management of symptoms. They promote communication between patients and health professionals and enhance patients' involvement in care and treatment planning and decision. 73 Research evidence indicated that the use of PROMs as part of routine clinical care for cancer patients increases patient satisfaction with care, 73 and improves symptom management and overall QoL, 74, 75 leading to less frequent hospitalization and better survival rates. 74 The current study mainly aimed to review the validated PROMs used to measure pain as one of the significant symptoms for cancer. This provides healthcare professionals with an evidence-based selected instrument. The review found 3,398 studies from which 3,373 studies were excluded on the title and abstract screening stage to end with 25 studies. Nine further studies were excluded at the full text screening stage due to the reasons detailed in Figure 1 . Sixteen studies that evaluated 8 pain measurement instruments were included in the review. These studies were conducted in various countries, so the languages of the instruments were also heterogeneous (see Table 1 ). The studies and their results for the measurement properties were systematically reviewed and appraised using the COSMIN checklist and good measurement properties criteria proposed by the COSMIN group, respectively (see Table 3 ). The strength of evidence was identified, based on the COSMIN best evidence synthesis guidelines, for each of the evaluated measurement properties per instrument, as shown in Table 4 .
Internal consistency was assessed in all the included instruments. Construct validity and structural validity were the second most frequently evaluated measurement properties. Cross-cultural validity was evaluated in 10 studies, 7 of which were about the BPI. Reliability was addressed in only 3 instruments. The remaining measurement properties, that is, measurement error, content validity, and responsiveness, were not tested in any instrument (see Table 2 ). Fifty-two of the sixty methodological qualities of the evaluated measurement properties ranged between poor and fair quality. The low ratings were generally due to insufficient sample sizes, vague or not previously formulated hypotheses, lack of information regarding the handling of missing items or regarding the constructs being measured by the comparator instruments or their measurement properties, internal consistency statistics not being calculated for each subscale individually, and multiple-group CFA not being performed for translated instruments.
The evidence synthesis presented in Table 4 shows that no instrument had strong positive evidence for all the evaluated measurement properties. Therefore, no strong recommendation can be derived from the available evidence in relation to identifying a fully validated pain measurement instrument for adult cancer patients. Based on the available evidence, the BPI-SF is the best evaluated instrument, as it shows moderate positive evidence in internal consistency, construct validity, and structural validity, whereas none of the other instruments showed comparable evidence. Indeed, the full BPI and MPQ-SF-2 showed stronger positive evidence for internal consistency compared to the BPI-SF. On the other hand, the BPI showed negative structural validity as reported by several fair methodological studies; this resulted in moderate negative evidence, while the BPI-SF had moderate positive evidence. The MPQ-SF-2 also showed negative structural validity in addition to inadequate evidence for the other measurement properties, indicating that the BPI-SF has greater validity.
The results of this review should be interpreted with caution. It should not be presumed that the instruments for which it was not possible to establish adequate validity are invalid. Typically, there was insufficient evidence to establish their validity; information was missing and the quality of the available research was inadequate. Therefore, more validation studies of better quality are needed to address all the measurement properties of the identified instruments and to reveal more about their quality.
This review did not identify any studies that used pain measurement instruments in a smartphone or tablet app for adult cancer patients, which establishes the valuable opportunity for future research in this area. In fact, a study aiming to develop a system that utilizes an app based on a validated pain measurement scale to record pain has been initiated. The results of the current study inform the choice of the scale.
STRENGTHS AND LIMITATIONS
This systematic review was informed by Cochrane guidelines and COSMIN protocol. This approach has added to the robustness of the study. Cochrane is particularly tailored to systematic reviews of RCTs, and this study was oriented to the analysis of measurement properties. As the former is well accredited and has more structured search strategy guidelines, it was used in line with the protocol to ensure advantages of both to achieve the aim of the review. COSMIN recommends building the search strategy in combination with a search filter for finding studies on measurement properties. 29, 76 However, when this was piloted, it retrieved far fewer relevant studies compared to using Cochrane guidelines for constructing the search strategy and filtering the search using the Oxford filter. This may be because the COSMIN filter for measurement properties studies is designed and validated for PubMed 76 and is not validated for the databases used in this review.
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Using the Oxford filter is a probable explanation for not identifying any mHealth apps using PROMs for pain. While there may be mHealth apps for pain, the filter successfully excluded them because they did not use PROMs.
This study has some limitations. The assessment of the studies and measurement properties was limited in some instances by lack of information available in some papers. In these instances, no further information was sought from the original authors. In addition, the review was restricted to English language publications only; we acknowledge that validation studies may have been published in other languages, which may provide further insight into these tools.
CONCLUSION
Sixteen studies were identified, but little evidence of thorough evaluation of pain tools. Given the extent of current published evidence, the BPI-SF is the most appropriate instrument. More validation studies of better quality are desired.
Utilizing mHealth apps for measuring pain in cancer patients is an innovative approach worthy of further investigation. A study in this area is established.
APPENDIX 1 COSMIN's Definitions of the Measurement Properties
Domain
Measurement Property Definition from Mokkink et al. 38 Reliability "The degree to which the measurement is free from measurement error." Reliability (extended definition) "The extent to which scores for patients who have not changed are the same for repeated measurement under several conditions: for example, using different sets of items from the same HR-PROs (internal consistency), over time (testeretest) by different persons on the same occasion (interrater) or by the same persons (ie, raters or responders) on different occasions (intrarater)." Internal consistency "The degree of the interrelatedness among the items." Reliability "The proportion of the total variance in the measurements which is because of ''true'' differences among patients." Measurement error "The systematic and random error of a patient's score that is not attributed to true changes in the construct to be measured." Validity "The degree to which an HR-PRO instrument measures the construct(s) it purports to measure." Content validity "The degree to which the content of an HR-PRO instrument is an adequate reflection of the construct to be measured." Construct validity (or hypotheses testing)
"The degree to which the scores of an HR-PRO instrument are consistent with hypotheses (for instance with regard to internal relationships, relationships to scores of other instruments, or differences between relevant groups) based on the assumption that the HR-PRO instrument validly measures the construct to be measured." Structural validity "The degree to which the scores of an HR-PRO instrument are an adequate reflection of the dimensionality of the construct to be measured." Cross-cultural validity "The degree to which the performance of the items on a translated or culturally adapted HR-PRO instrument are an adequate reflection of the performance of the items of the original version of the HR-PRO instrument." Criterion validity "The degree to which the scores of an HR-PRO instrument are an adequate reflection of a 'gold standard'." Responsiveness Responsiveness "The ability of an HR-PRO instrument to detect change over time in the construct to be measured." 
